MorphoSys Initiates Infectious Disease Alliance with ContraFect
Combinatorial Approach Using Multi-Therapy Antibody Treatment
12-Apr-2011 -
MorphoSys AG announced the formation of a new alliance with US-based biotechnology company ContraFect Corp. in the discovery and development of therapeutic antibodies for infectious diseases. Under the terms of the five-year agreement, ContraFect will receive access to HuCAL PLATINUM, the latest ...
infectious diseases
monoclonal antibodies